Whilst other NGS workflows are advertised as “end to end” and “automated”, we believe that the Ion Torrent™ Genexus™ System and assay menu represents the only true end to end solution at the market. 2 instruments, 1 software and assays, all from one supplier will enable you go from biological specimen to report in as little as 1 day, involving only 20 min hand on time.
Read the latest news and user stories about how the Genexus System is advancing precision oncology in our quarterly e-news.
In this issue, we bring you a number of new stories, testimonials, and data from Genexus System users. But first, we want to share that we are working hard on making the Genexus System, and a number of next-generation sequencing (NGS) assays, compliant with the new In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746. Read more.
Enjoy this five-part on-demand series that gives you a closer look at the new Genexus System and FusionSync technology.
Are you worried about NGS bioinformatics? Using different software and requiring an expert to stich it all together? No need anymore! The Genexus Software, one secure, streamlined and easy-to-use NGS analysis software, provides a seamless experience from end to end, starting with entering sample data and finishing with report.
The Oncomine Reporter delivers clear and concise reports that present all relevant variants with annotated information about targeted therapies, guidelines, and enrollment of ongoing clinical trials.
The report is customizable so that you can tailor it to fit your team's needs.
A molecular biology laboratory at the Hospital Universitari Vall d'Hebron performs NGS analysis with the Genexus System.
The Oncomine Precision Assay on the Ion Torrent Genexus System detects low-level variants that are particularly important for liquid biopsy testing. It provides:
Although tissue samples are still the gold standard for molecular profiling, there exist many limitations.
Tissue can be inaccessible or there may not be enough material to sequence. Further, obtaining a tissue sample is difficult to repeat and not useful for monitoring and the sample may not reflect tumor heterogeneity. Liquid biopsy may be a viable alternative to tissue sequencing, as it is minimally invasive, provides a comprehensive tumor profile, and allows for repeat sampling.
With the Oncomine Precision Assay, you have the flexibility to sequence standard tissue or minimally invasive plasma samples, from one test on a single workflow.
1. Next-Generation Sequencing in 305 Consecutive Patents: Clinical Outcomes and Management Changes; Gregory J. Kubicek, MD., et al., Journal of Clinical Oncology, Aug. 2019.
2. J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.
3. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer; Jason Zhu, et al.; Urologic Cancer: Seminars and Original Investigations, July 2019.
4. Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine™ TML and FoundationOne™ assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Heeke S. et al. DOI: 10.1158/1538-7445.AM2019-4889; July 2019.
For Research Use Only. Not for use in diagnostic procedures.